Riskpilot← Back to searchSign inGet full accessASCENDIS PHARMA A/S
A/SActiveCVR 29918791Tuborg Boulevard 12Manufacture of pharmaceutical preparations · NACE 2120Est. 2006655 employees
Revenue 2023
DKK 302,7M
+492% vs 2022
EBITDA margin
-1.1%
+99% vs 2022
Equity ratio
—
Financial strength
Net profit 2023
DKK 39,7M
+107% vs 2022
| Revenue | DKK 302,7M | +492% |
| EBITDA | DKK -3,2M | +99% |
| Net profit | DKK 39,7M | +107% |
| Total assets | DKK 0 | -100% |
| Equity | — | — |
| Employees | 655 | — |
Legal name
ASCENDIS PHARMA A/S
CVR number
29918791
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
21. september 2006
Share capital
DKK 62.376.846
Employees
655 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2023-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med en direktør, af to direktører i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at udvikle idèer og præparater til sygdomsbekæmpelse ad medicinsk vej, at producere og sælge sådanne præparater eller idèer, at eje aktier i selskaber med samme formål samt at udøve virksomhed, som står i naturlig forbindelse hermed.
Address
Tuborg Boulevard 12
Phone
+4536944486
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | 118.542 | — | 13.132 | 7.785 | 15.434 | 21.096 | 25.288 | 40.447 | 69.112 | 7.778 | 51.174 | 302.712 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -6.086 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | — | — | — | — | — | 55.068 | — | -3.977 | -15.579 | -20.623 | -23.290 | -43.810 | -81.707 | -112.461 | -451.792 | -561.814 | -3.191 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | — | — | — | — | — | 55.068 | — | -3.977 | -15.579 | -20.623 | -23.290 | -43.810 | -81.707 | -112.461 | -451.792 | -561.814 | -3.191 |
| Net financials | 0 | 0 | 0 | 0 | 0 | -46.130 | 0 | 1.467 | 8.638 | 5.581 | -8.581 | 30.652 | 27.226 | -63.133 | 67.848 | -16.003 | 42.910 |
| Profit before tax | — | — | — | — | — | 8.938 | — | -2.510 | -6.941 | -15.042 | -31.871 | -13.158 | -54.481 | -175.594 | -383.944 | -577.817 | 39.719 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -823 | -801 | -752 | -739 | -737 | 950 | -363 | -367 | 5.377 | 3 |
| Net profit | — | — | — | — | — | 8.938 | — | -1.687 | -6.140 | -14.290 | -31.132 | -12.421 | -55.431 | -175.231 | -383.577 | -583.194 | 39.716 |
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 0 | 0 | 0 | 0 | 0 | 202.831 | 0 | 76.593 | 175.555 | 291.779 | 406.090 | 628.208 | 1.129.800 | 1.616.367 | 1.084.921 | 1.089.738 | 0 |
| Equity | — | — | — | — | — | 134.644 | — | 60.542 | 161.857 | 272.350 | 375.648 | 586.146 | 1.065.832 | 1.551.195 | 883.635 | 263.348 | — |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.619 | 12.877 | 100.930 | 655.119 | 0 |
| Short-term debt | 0 | 0 | 0 | 0 | 0 | 68.187 | 0 | 16.051 | 13.698 | 19.429 | 30.442 | 42.062 | 54.349 | 52.295 | 99.163 | 163.932 | 0 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 68.187 | 0 | 16.051 | 13.698 | 19.429 | 30.442 | 42.062 | 63.968 | 65.172 | 200.093 | 819.051 | 0 |
EBITDA margin
-1.1%
This company
15.8%
Market median
-107% vs market
20072023
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20072023
Return on equity
3971600000.0%
This company
18.4%
Market median
+21584782509% vs market
20072023
Net profit margin
13.1%
This company
8.1%
Market median
+62% vs market
20072023
Asset turnover
302712000.00×
This company
1.12×
Market median
+27027857043% vs market
20072023
Debt / equity
-1.00×
This company
0.62×
Market median
+261% vs market
20072023
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via CVR / Virk · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via CVR / Virk · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via CVR / Virk · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via CVR / Virk · Period 2008-01-01 – 2008-12-31
- Annual report 2007Filed via CVR / Virk · Period 2006-09-21 – 2007-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MW Management | Management | 2021 | — | — |
AL Management | Management | 2021 | — | — |
RA Chief Executive Officer | Chief Executive Officer | 2006 | — | — |
JM Chief Executive Officer | Chief Executive Officer | 2007 | — | — |
ST Management | Management | 2016 | — | — |
TP Management | Management | 2014 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2007 | — | — | |
| Board of Directors | 2014 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2007 | — | — | |
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2008 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2013 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 90.0% | 90.0% | 2020 | |
| Individual | 5.0% | 5.0% | 2014 | |
| Individual | 66.7% | 66.7% | 2015 | |
| Individual | 5.0% | 5.0% | 2011 | |
| Individual | 20.0% | 20.0% | 2014 | |
| Individual | 5.0% | 5.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ASCENDIS PHARMA A/S 
ASCENDIS PHARMA BONE DISEASES A/SBoard members of ASCENDIS PHARMA A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Michael Wolff Jensen | Management | 0 companies |
| Anni Lotte Kirstine Pedersen | Management | 0 companies |
| Rigele Abilock | Chief Executive Officer | 0 companies |
| Jan Møller Mikkelsen | Chief Executive Officer | 0 companies |
| Scott Thomas Smith | Management | 0 companies |
| Thomas Paul Soloway | Management | 0 companies |
| Jonathan Silverstein | Board of Directors | 0 companies |
| Rafaèle Tordjman | Board of Directors | 0 companies |
| Michael Gerhard Mayer | Board of Directors | 0 companies |
| Jim Healy | Board of Directors | 0 companies |
| Albert Cha | Chairman | 0 companies |
| Lars Holtug | Board of Directors | 0 companies |
| Edwin William de Graaf | Board of Directors | 0 companies |
| Birgitte Volck | Board of Directors | 0 companies |
| Dirk Kersten | Board of Directors | 0 companies |
| Martin Olin | Board of Directors | 0 companies |
| Siham Imani | Board of Directors | 0 companies |
| Lisa Jane Morrison | Board of Directors | 0 companies |
| William Carl Fairey Jr | Board of Directors | 0 companies |
| Rafaèle Elisabeth Tordjman | Board of Directors | 0 companies |
| Jean-Jacques Bienaime | Board of Directors | 0 companies |
| William Robert Ringo | Board of Directors | 0 companies |